

**WAC 296-62-07302 Communication of hazards.** (1) Hazard communication.

(a) Chemical manufacturers, importers, distributors, and employers must comply with all requirements of the Hazard Communication Standard (HCS), WAC 296-901-140 for each carcinogen listed in subsection (2) of this section.

(b) In classifying the hazards of carcinogens listed in subsection (2) of this section, at least the hazards listed in subsection (2) of this section are to be addressed.

(c) Employers must include the carcinogens listed in subsection (2) of this section in the hazard communication program established to comply with the HCS, WAC 296-901-140. Employers must ensure that each employee has access to labels on containers of the carcinogens listed in subsection (2) of this section and to safety data sheets, and is trained in accordance with the requirements of HCS and subsection (2) of this section.

(2) List of carcinogens:

(a) 4-Nitrobiphenyl: Cancer (CAS 92-93-3).

(b) Alpha-Naphthylamine: Cancer; skin irritation; and acute toxicity effects (CAS 134-32-7).

(c) Methyl chloromethyl ether: Cancer; skin, eye and respiratory effects; acute toxicity effects; and flammability (CAS 107-30-2).

(d) 3,3'-Dichlorobenzidine (and its salts): Cancer and skin sensitization (CAS 91-94-1).

(e) Bis-Chloromethyl ether: Cancer; skin, eye, and respiratory tract effects; acute toxicity effects; and flammability (CAS 542-88-1).

(f) Beta-Naphthylamine: Cancer and acute toxicity effects (CAS 91-59-8).

(g) Benzidine: Cancer and acute toxicity effects (CAS 92-87-5).

(h) 4-Aminodiphenyl: Cancer (CAS 92-67-1).

(i) Ethyleneimine: Cancer; mutagenicity; skin and eye effects; liver effects; kidney effects; acute toxicity effects; and flammability (CAS 151-56-4).

(j) Beta-Propiolactone: Cancer; skin irritation; eye effects; and acute toxicity effects (CAS 57-57-8).

(k) 2-Acetylaminofluorene: Cancer (CAS 53-96-3).

(l) 4-Dimethylaminoazo-benzene: Cancer, skin effects; and respiratory tract irritation (CAS 60-11-7).

(m) N-Nitrosodimethylamine: Cancer; liver effects; and acute toxicity effects (CAS 62-75-9).

[Statutory Authority: RCW 49.17.010, 49.17.040, 49.17.050, and 49.17.060. WSR 19-01-094, § 296-62-07302, filed 12/18/18, effective 1/18/19. Statutory Authority: RCW 49.17.010, 49.17.040, 49.17.050, 49.17.060 and 29 C.F.R. 1910 Subpart Z. WSR 14-07-086, § 296-62-07302, filed 3/18/14, effective 5/1/14. Statutory Authority: RCW 49.17.010, [49.17].040, [49.17].050. WSR 02-12-098, § 296-62-07302, filed 6/5/02, effective 8/1/02. Statutory Authority: Chapter 49.17 RCW. WSR 94-15-096 (Order 94-07), § 296-62-07302, filed 7/20/94, effective 9/20/94. Statutory Authority: RCW 49.17.040 and 49.17.050. WSR 85-10-004 (Order 85-09), § 296-62-07302, filed 4/19/85; WSR 82-13-045 (Order 82-22), § 296-62-07302, filed 6/11/82; WSR 81-07-048 (Order 81-4), § 296-62-07302, filed 3/17/81. Statutory Authority: RCW 49.17.040, 49.17.050, 49.17.240, chapters 42.30 and 43.22 RCW. WSR 80-17-014 (Order 80-20), § 296-62-07302, filed 11/13/80.]